OncoDNA
Business Services · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Rue Louis Breguet 1, Gosselies, Wallonia...Phone Number
+32 71183500Website
www.oncodna.comRevenue
$5.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About OncoDNA
Founded in 2012 and headquartered in Belgium, OncoDNA aims to provide cancer molecular profiling to individualize therapy decisions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OncoDNA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on OncoDNA recently announced quarterly report
Check if OncoDNA has recently received funding, and reach out quickly before it becomes old news!
OncoDNA, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when OncoDNA launches new products
Website visits: Recent activity has been detected on your website
Click to see if OncoDNA had a recent Job posting/layoffs
Funding: Get notified immidiatlly once OncoDNA has new funding data
Check out if OncoDNA is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at OncoDNA
Recommended Actions
Reach out to Masked Content who joined OncoDNA as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
OncoDNA is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
OncoDNA is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about OncoDNA.
OncoDNA financials insights
Gather financial insights about OncoDNA, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$8.6M
2020
Series B
$20M
OncoDNA Tech Stack
A closer look at the technologies used by OncoDNA
See more technologies
Most Recent Scoops
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
New Hire
Executive Move
New Hire
Executive Move
Left Company
Executive Move
Funding
Funding
OncoDNA News & Media
PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project
LIÈGE, Belgium & GRENOBLE, France--(BUSINESS WIRE)--PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia. This is the result of a call for proposals on R&D projects in the field of Advanced Therapy Medicinal Products (ATMP). Members of the project consortium will receive €8.1M ($8.9M)C2i Genomics Partners with OncoDNA to Bring AI-Powered Liquid Biopsy for Cancer Diagnostics Across Europe
C 2i Genomics, a cancer intelligence company, today announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers across Europe. The company will act as a primary lab partner, operating C2i's whole-genome seque... ReadRiassunto: La lotta al cancro con vaccini personalizzati: OncoDNA e myNEO uniscono le forze per scatenare il potere delle terapie a base di mRNA
GOSSELIES, Belgio--(BUSINESS WIRE)--OncoDNA, azienda teranostica e genomica specializzata nella medicina di precisione, e myNEO, società basata sull'AI che sta rivoluzionando l'identificazione mirata all'interno della immuno-oncologia, sono entusiaste di annunciare una nuova collaborazione che rivoluzionerà la cura oncologica. Le due società sono giunte a un accordo sul consolidamento delle loro tecnologie di base per consentire la produzione di vaccini personalizzati destinati a pazienti che hResumen: Luchar contra el cáncer con vacunas personalizadas: OncoDNA y myNEO aúnan sus fuerzas para poner de manifiesto el poder del ARNm
GOSSELIES, Bélgica--(BUSINESS WIRE)--OncoDNA, empresa especializada en teranóstica y genómica para la medicina de precisión, y myNEO, empresa de IA que revoluciona la identificación de dianas dentro de la inmunooncología, se complacen en anunciar una nueva colaboración que revolucionará el tratamiento del cáncer. Las dos empresas han acordado consolidar sus principales tecnologías para permitir la producción de vacunas personalizadas para los pacientes que se han quedado sin opciones de tratami
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding OncoDNA
Sign Up For FreeTo access detailed company insights
Founded in 2012 and headquartered in Belgium, OncoDNA aims to provide cancer molecular profiling to individualize therapy decisions.... Read More
